Jump to content

User:Mr. Ibrahem/Belumosudil

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Belumosudil
Clinical data
Trade namesRezurock, Rholistiq
Other namesKD025, SLx-2119
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		By mouth
Legal status
Legal status
Identifiers
  • 2-[3-[4-(1H-Indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide
Chemical and physical data
FormulaC26H24N6O2
Molar mass452.518 g·mol−1
3D model (JSmol)
  • CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5
  • InChI=InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31) checkY
  • Key:GKHIVNAUVKXIIY-UHFFFAOYSA-N checkY

Belumosudil, sold under the brand name Rezurock among others, is a medication used to treat chronic graft versus host disease (cGvHD).[5] It is used in those who are at least 12 years of age who do not improve after other treatments.[5] It is taken by mouth.[5]

Common side effects include infections, weakness, nausea, diarrhea, shortness of breath, cough, swelling, bleeding, abdominal pain, musculoskeletal pain, headache, low phosphate, low lymphocytes, and high blood pressure.[5] Use in pregnancy may harm the baby.[5] It is a kinase inhibitor; specifically of Rho-associated coiled-coil kinase 2 (ROCK2).[6][7]

Belumosudil was approved for medical use in the United States in 2021.[5] While it is approved in the United Kingdom, it is not in the rest of Europe as of 2022.[7] In the United States it costs about 17,000 USD per month as of 2022.[8] In the UK, a one month supply costs the NHS around £6,700 as of 2023.[9]

References[edit]

  1. ^ a b "Rholistiq". Therapeutic Goods Administration (TGA). 26 November 2021. Archived from the original on 28 December 2021. Retrieved 28 December 2021.
  2. ^ a b "AusPAR: Belumosudil". Therapeutic Goods Administration (TGA). 10 May 2022. Archived from the original on 10 May 2022. Retrieved 10 May 2022.
  3. ^ "Archived copy" (PDF). Archived (PDF) from the original on 29 June 2022. Retrieved 29 June 2022.{{cite web}}: CS1 maint: archived copy as title (link)
  4. ^ "Summary Basis of Decision - Rholistiq". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.
  5. ^ a b c d e f g h i "Rezurock- belumosudil tablet". DailyMed. Archived from the original on 21 August 2021. Retrieved 20 August 2021.
  6. ^ a b "FDA approves belumosudil for chronic graft-versus-host disease". U.S. Food and Drug Administration (FDA). 16 July 2021. Archived from the original on 16 July 2021. Retrieved 16 July 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  7. ^ a b "Belumosudil". SPS - Specialist Pharmacy Service. 23 April 2021. Archived from the original on 27 October 2022. Retrieved 29 October 2022.
  8. ^ "Rezurock Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 29 October 2022.
  9. ^ "8. Immune system and malignant disease". BNF 86: September 2023 - March 2024. BMJ Group and the Pharmaceutical Press. 2023. pp. 933–934. ISBN 978-0857114617.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Belumosudil&oldid=1225054300"